Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs

C A Bloom; M A Labato; S Hazarika; M H Court

doi:10.1111/j.1365-2885.2011.01319.x

Back

Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs

Journal article

Open access

Peer reviewed

Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs

C A Bloom, M A Labato, S Hazarika and M H Court

Journal of veterinary pharmacology and therapeutics, Vol.35(3), pp.224-230

06/2012

DOI: https://doi.org/10.1111/j.1365-2885.2011.01319.x

Handle:

https://hdl.handle.net/2376/108619

PMID: 21732952

Files and links (1)

url

https://doi.org/10.1111/j.1365-2885.2011.01319.xView

Published (Version of record) Open

Abstract

Respiratory Rate - drug effects

Male

Chromatography, High Pressure Liquid

Fenoldopam - pharmacology

Heart Rate - drug effects

Animals

Fenoldopam - pharmacokinetics

Dogs

Fenoldopam - administration & dosage

Receptors, Dopamine D1 - agonists

Female

Fenoldopam - blood

Blood Pressure - drug effects

Infusions, Intravenous

Fenoldopam is a selective dopamine-1 receptor agonist that causes peripheral arterial vasodilation, increased renal blood flow, and diuresis. Enthusiasm exists for the use of fenoldopam in nonpolyuric kidney injury in dogs, although pharmacokinetic data are lacking. The purpose of this study was to collect basic pharmacokinetic and hemodynamic effect data for fenoldopam when administered to healthy awake dogs. Six healthy, awake beagles were given a 180-min fenoldopam constant rate infusion at 0.8 μg/kg per minute followed by a 120-min washout period. Citrated blood was collected during and after infusion for the measurement of plasma fenoldopam concentration by HPLC with mass spectrometry. Heart rate and indirect systolic blood pressure were concurrently measured. Mean ± SD, steady-state plasma fenoldopam concentrations of 20 ± 17 ng/mL were achieved within 10 min of starting the infusion. Area under the plasma concentration-time curve was 3678 ± 3030 ng/mL · min, and plasma clearance was 66 ± 43 mL/min per kg. Elimination was rapidly achieved in all dogs. Heart rate and systolic blood pressure were unaffected by the fenoldopam infusion. Based on the results of this study, further evaluation of the effects of fenoldopam in dogs at differing doses and in dogs with clinical conditions such as acute nonpolyuric kidney injury is warranted.

Metrics

10 Record Views

Details

Title: Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs
Creators: C A Bloom - Tufts University Cummings School of Veterinary Medicine, North Grafton, MA, USA. carly_bloom@hotmail.com
M A Labato
S Hazarika
M H Court
Publication Details: Journal of veterinary pharmacology and therapeutics, Vol.35(3), pp.224-230
Academic Unit: Veterinary Clinical Sciences, Department of
Publisher: England
Grant note: R01 GM061834-09 / NIGMS NIH HHS R01GM061834 / NIGMS NIH HHS R01 GM061834 / NIGMS NIH HHS
Identifiers: 99900547188401842
Language: English
Resource Type: Journal article